Ben Wang, PharmD, BCCP
@BenWangPharmD
Followers
187
Following
1K
Media
6
Statuses
284
Stanford Health Care CCU / PH Clinical Pharmacist | PGY-2 Cards Rx RPD | Views are my own.
Palo Alto, CA
Joined March 2018
Alteplase Purge Solution for Impella 5.5 @asaiojournal @JimmyZhengMD Impella purge system occlusion, often referred to as “Impella thrombosis” not always associated w/worse pump fxn/failure. We describe a case w/unchanged hemodynamics/flow + review of lit. https://t.co/QD4pVUdXLr
journals.lww.com
urge system occlusion in a 31-year-old male admitted to the cardiac care unit in cardiogenic shock and listed for a heart transplant. Throughout the purge system occlusion, the patient demonstrated...
1
3
11
We're proud to announce that #StanDOM's Karim Sallam has been named the 2025 recipient of the Alwin C. Rambar – James B.D. Mark Award for Excellence in Patient Care. His compassion, dedication & teamwork define excellence at @StanfordMed. Congratulations, Karim!
3
9
51
Check out our new blog, Features from FITs!!
How can we combat implicit bias in cardiology training? Read our💫editorial fellow @najahakhan discuss her own experiences navigating microaggressions as a South Asian #WIC. While you're at it: subscribe to our new blog, Features from FITs, to read more! https://t.co/WQfFosIYRG
0
2
7
*JOIN US* Wed, June 4 from 2–7:30 pm ET is the 3rd CSWG Global Summit—featuring real-world cases, lightning talks, debates & panels. This global, virtual event is FREE to attend. Registration is open at https://t.co/LZ7FdeeXQT. #CSWG #CardioShock #CSWG25
cardiogenicshocksummit.org
Join the Cardiogenic Shock Working Group for its third Global Summit—a free, fully virtual 5-hour event on Wednesday, June 4, 2025, focused on improving patient outcomes in cardiogenic shock. This...
1
12
22
#SGLT2i therapy was associated with an overall lower risk of atrial arrhythmia and SCD in patients with #T2D mellitus and/or #heartfailure or #CKD. However, SGLT2i therapy was not associated with a lower risk of ventricular arrhythmia. https://t.co/OgQUjJiDiw
#JACCAdvances
0
32
88
Hey pharmacists! Check out this webinar on how to start a heart failure clinic: https://t.co/rwBnLJWQZP
@UMichPharmacy @accpcardprn @beaverspharmd @PharmacistHF @AACPharmacy
0
7
35
Most impactful trial of #ACC25 imo. Early stoppage limits assessment of mortality as individual endpoint, but effect estimate is strong. Huge win for these patients! @accpcardprn @ACCPpulmPRN @ZRSmith16 @BenWangPharmD
Presented at #ACC25: Among adults with pulmonary arterial hypertension at high risk for death, sotatercept reduced the risk of a composite of death from any cause, lung transplantation, or pulmonary arterial hypertension. Full ZENITH trial results: https://t.co/HJRCr08S8K
0
2
7
ACC 2025 LATE BREAKING CLINICAL TRIALS - One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congratulations to all the presenters &research leaders for yet another fantastic year of innovation & research. 🫀❤️ 😊 #ACC2025 @ACCinTouch @uw_cvm @CardioNerds
0
139
345
Proud to introduce a new endeavor in partnership with @Pharmacy_Times @MJHLifeSciences…The Tell-Tale Heart: A Pharmacist Cardiovascular Digest. Check out our intro episode here or where you get your podcast and follow every 2 weeks: https://t.co/DGKGIrQesD
2
10
37
REMINDER - Our March Journal Club presentation is TOMORROW at 2:00 PM EST (see communities post for link)! Join us as Drs. Josephine Ngo and Matthew Louie, PGY2 Cardiology Residents at the UC Davis Medical Center, present on the POPular PAUSE TAVI trial and OCEAN-TAVI registry!
0
2
4
Got burning questions about research methods? Don't miss our session on March 25 at 12 pm EST! We'll explore how to manage missing data in observational studies with @wbaker0621 using a heart transplant registry example. See communities page for link. Mark your calendars now! 📅
0
3
12
Is there finally a verdict on MRAs in HFmrEF/HFpEF? This recent #JCFIgnite! re-examines the data and finds that both steroidal and non-steroidal MRAs may be beneficial 💪 🔗 https://t.co/gCOzLkXlix
0
7
14
Our next Journal Club presentation is Tuesday, March 25th at 2:00 PM EST (see communities post for link)! Join us as Drs. Josephine Ngo and Matthew Louie, PGY2 Cardiology Residents at the UC Davis Medical Center, present on the POPular PAUSE TAVI trial and OCEAN-TAVI registry!
0
3
8
🚨Comprehensive review of RV failure after LVAD by @TuftsMedicalCtr’s Mike Kiernan for @Stanford Cards GR. So impactful, but hard to manage & mitigate‼️ #ThePeoplesVentricle
@RyanTedfordMD @TomCascinoMD @ISHLT @HFSA @TheJHLT @JCardFail @Stanford_HF
2
9
52
Virtual meeting link provided via the @accpcardprn list serv, though you may feel free to message me for the link if you are interested and not already a part of ACCP.
0
0
1
How fitting for us to discuss mentorship on match day with this star studded cast! @JackPluenneke @StephDwyer21 @jimcoons77 Robert Page II, PharmD
Has a mentor made a positive impact on your career? Have you served as a mentor for others? The Student/Trainee Committee is excited to host a 1hr professional development session this month called "Mentorship Through the Career Stages". Please see attached flyer for details!
1
2
6
🌟 Check out this excellent resource for Periprocedural Management of Anticoagulation! #AnticoagStewardship
Clinicians, are you looking for quick, reliable guidance on managing anticoagulation in patients undergoing non-emergent procedures? Our new Rapid Resource simplifies this complex process, helping you make informed decisions and optimize patient care. This concise guide provides
0
6
11
#Immunotherapy saves lives, but it can harm the heart. A new study finds that blocking CXCR3 prevents deadly heart inflammation without reducing cancer-fighting power. More from #StanDOM's @HanZhuMD:
med.stanford.edu
0
12
24
This. Decades of work & study. 10s of trials. 1000s of patients. Breakthrough discovery. Strident advocacy. Relentless QI. Are there still issues? ✅ But pause- where we were; where we are. For most patients, it’s not about failure but function. Not despair but opportunity.
No longer a disease of failure; after 100 years of tireless breakthrough science, HF is about function. @NMHheartdoc
https://t.co/WpdkJJLAdU
6
32
120
@JTThibs @SJGreene_md The only therapeutic strategy demonstrated in prospective RCTs to reduce HF hospitalizations and CV deaths have been the components of Q-GDMT Rapid separation of clinical event curves Improvement in health status Incremental/additive Highly cost effective
1
5
13
✅ out our 📑 and a commentary of our 📑 on #digoxin for rate control of atrial arrhythmias in the #CICU & #CTICU 🫀 https://t.co/NIFqQiPYUB
@ColombianpharmD @CardsNYC @jameshorowitzmd @SamuelB316 @JPCritCarePharm @JCVPOnline @nyulangone @nyugrossman
journals.lww.com
or pharmacokinetic-based calculation to target a serum digoxin concentration (SDC) of 0.8–1.5 ng/mL is recommended. The objective of this study was to assess the safety and effectiveness of digoxin...
Optimizing Digoxin Use in Critically Ill Patients: Lessons from a Retrospective Study https://t.co/TbErpJGNsC
@MarcoDelBuono3 @simonefilomia
#Digoxin #AtrialFibrillation #CriticalCare #Pharmacology #Cardiology
0
6
7